Conference item
Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola
- Abstract:
- The 2014-2016 Ebola outbreak in West Africa was the largest in history leading to 28,639 cases, of which 40% were fatal. Better treatments and effective vaccines against Ebola virus are needed to prevent future recurrence. Multiple, novel, treatment options were assessed during the outbreak, including ZMapp™ monoclonal antibody therapy, which showed promising results in some patients. However, widespread adoption of this approach is hindered by high costs of monoclonal antibody manufacturing and the relatively short half-life of antibody in the blood circulation. To circumvent such limitations, we propose to utilise recombinant adeno-associated virus (rAAV) delivered to the muscle to express the therapeutic monoclonal antibodies.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 60.3KB, Terms of use)
-
- Publisher copy:
- 10.1016/j.ymthe.2017.04.025
Authors
- Publisher:
- Elsevier
- Host title:
- American Society of Gene and Cell Therapy Annual Meeting (ASCGT 2017)
- Journal:
- MOLECULAR THERAPY More from this journal
- Series:
- Molecular Therapy
- Publication date:
- 2017-05-04
- Acceptance date:
- 2017-03-28
- DOI:
- Pubs id:
-
pubs:717384
- UUID:
-
uuid:3dcbec8c-3e81-46c2-857b-90ecee9b574b
- Local pid:
-
pubs:717384
- Source identifiers:
-
717384
- Deposit date:
-
2018-08-06
- ARK identifier:
Terms of use
- Copyright holder:
- Gill et al
- Copyright date:
- 2017
- Notes:
- © 2017. Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
If you are the owner of this record, you can report an update to it here: Report update to this record